Results 1 to 10 of about 15,206,096 (240)

Management of children and adolescents with Wilson Disease and neurological worsening following D–Penicillamine therapy: A single centre experience [PDF]

Annals of Indian Academy of Neurology, 2022
Background: Most centers in developing countries prefer chelation therapy with D-penicillamine for the management of Wilson's disease (WD) because of its easy availability and affordability. Neurological worsening following treatment with D-penicillamine
Madhan Kumar, T P Murugan, Arul P Lionel, Maya M Thomas, Pavithra Mannam, Sangeetha Yoganathan   +5 more
doaj   +3 more sources

Comparison of the Effectiveness and Safety of d-Penicillamine and Zinc Salt Treatment for Symptomatic Wilson Disease: A Systematic Review and Meta‐Analysis [PDF]

Frontiers in Pharmacology, 2022
Background: Pharmacological therapy is currently the main treatment method for patients with Wilson disease (WD). We aimed to evaluate the efficacy and safety of the common treatment regimens in these patients.Methods: We conducted a systemic review and ...
Shan Tang, Li Bai, Li Bai, Wei Hou, Zhongjie Hu, Xinyue Chen, Jing Zhao, Chen Liang, Wei Zhang, Zhongping Duan, Sujun Zheng   +10 more
doaj   +3 more sources

D-Penicillamine: The State of the Art in Humans and in Dogs from a Pharmacological and Regulatory Perspective [PDF]

Antibiotics, 2021
Chelant agents are the mainstay of treatment in copper-associated hepatitis in humans, where D-penicillamine is the chelant agent of first choice. In veterinary medicine, the use of D-penicillamine has increased with the recent recognition of copper ...
Michela Pugliese, Vito Biondi, Enrico Gugliandolo, Patrizia Licata, Alessio Filippo Peritore, Rosalia Crupi, Annamaria Passantino   +6 more
doaj   +3 more sources

D-penicillamine induced degenerative dermopathy

Indian Journal of Dermatology, 2015
D-penicillamine interferes with elastin and collagen metabolism and produces several cutaneous and multi-systemic side-effects. We present two cases of Wilson′s disease who on long-term penicillamine therapy developed drug-induced degenerative dermopathy
Sujay Khandpur, Naresh Jain, Shweta Singla, Priti Chatterjee, Madhuri Behari   +4 more
doaj   +6 more sources

D-penicillamine Induced Myasthenia Gravis in Wilson’s Disease: A Case Report [PDF]

Journal of Nepal Medical Association, 2022
Myasthenia gravis is a neuromuscular junction disorder characterised by fluctuating muscle weakness, improved by using anti-cholinesterase drugs. In addition to the autoimmune aetiology, various factors such as infections, surgery, and drugs are known ...
Lekhjung Thapa, Monika Thapa, Suman Bhattarai, Abhishek Man Shrestha, Nooma Sharma, Nilshan Rai, Merina Pokharel, Raju Paudel   +7 more
doaj   +2 more sources

Outcomes of Tiopronin and D-Penicillamine Therapy in Pediatric Cystinuria: A Clinical Comparison of Two Cases [PDF]

Reports
Background and Clinical Significance: Cystinuria is the most common genetic cause of pediatric nephrolithiasis, characterized by impaired renal cystine reabsorption and resulting in increased urinary cystine excretion.
Brooke Schaefer, Adinoyi Garba, Xiaoyan Wu   +2 more
doaj   +2 more sources

D-Penicillamine-Induced Myasthenia Gravis—A Probable Complication of Wilson’s Disease Treatment—A Case Report and Systematic Review of the Literature [PDF]

Life, 2023
Wilson’s disease (WD) is a genetic disorder with copper accumulation in various tissues leading to related clinical symptoms (mainly hepatic and neuropsychiatric) which can be in 85% of patients successfully treated with anti-copper agents.
Agnieszka Antos, Anna Członkowska, Jan Bembenek, Iwona Kurkowska-Jastrzębska, Tomasz Litwin   +4 more
doaj   +2 more sources

Angiostatin generating capacity and anti-tumour effects of D-penicillamine and plasminogen activators [PDF]

BMC Cancer, 2006
Background Upregulation of endogenous angiostatin levels may constitute a novel anti-angiogenic, and therefore anti-tumor therapy. In vitro, angiostatin generation is a two-step process, starting with the conversion of plasminogen to plasmin by ...
Maass Cathy N, Lamers-Elemans Iris L, Ruers Theo JM, de Groot-Besseling Renate RJ, de Waal Robert MW, Westphal Johan R   +5 more
doaj   +2 more sources

Intracerebroventricular administration of the (1→6)-β-d-glucan (lasiodiplodan) in male rats prevents d-penicillamine-induced behavioral alterations and lipoperoxidation in the cortex [PDF]

Pharmaceutical Biology, 2017
Context: Lasiodiplodan, an exocellular (1→6)-β-d-glucan of molecular weight >1.4 × 106 Da produced by MMPI strain of Lasiodiplodia theobromae (Pat.) Griffon & Maubl.
Carlos Ricardo Maneck Malfatti, Fabio Seidel dos Santos, Jéssica Wouk, Luiz Augusto da Silva, Renan Garcia Michel, André Luiz Snak, Tiago Czervinski, Mário A. Alves da Cunha, Aneli M. Barbosa, Robert F. H. Dekker   +9 more
doaj   +2 more sources

D-penicillamine for primary biliary cirrhosis

Cochrane Database of Systematic Reviews, 2004
D-penicillamine is used for patients with primary biliary cirrhosis due to its hepatic copper decreasing and immunomodulatory potentials. The results from randomised clinical trials have been inconsistent.To systematically review the beneficial and harmful effects of D-penicillamine for patients with primary biliary cirrhosis.We identified trials ...
Yan Gong, Sarah Louise Klingenberg, Christian Gluud   +2 more
openalex   +4 more sources